Old and new treatment for ADHD -Tipepidine-
| Project/Area Number |
15K19712
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 注意欠如多動性障害 / ADHD / チペピジン / プラセボ対照 / ランダム化 / 二重盲検 / 児童精神医学 |
|---|
| Outline of Final Research Achievements |
We firstly planned 80 participants registration. However actual enrolled participants were 21 . 21 patricipants started this study (11 Placebo, 10 Tipepidine Hibenzate), One participant (placebo) of them canceled by himself hope, 20 participants completed (10 Placebo, 10 Tipepidine Hibenzate). There was no serious adverse event.
There was no significant difference between ADHD-RS total score (physician evaluation :primary), ADHD-RS inattentive subscore, hyper-impulsive subscore, DN-CAS score, CGI score and each time comparison (LS mean) .
|
| Academic Significance and Societal Importance of the Research Achievements |
チペピジンヒベンズ酸塩は1959年以来、我が国においてのみ鎮咳薬として薬価収載市販されており、ヒト（小児、成人）に対する安全性は確立されている。本試験は児童期ADHD患者に対するチペピジンヒベンズ酸塩の有効性を検討するための世界初のプラセボ対照二重盲検比較試験であった。本試験によりチペピジンヒベンズ酸塩の児童・思春期ADHD患者に対する有効性や忍容性が確認されれば、ADHDの治療発展に大きく貢献することが出来ると考えたが、ADHDの各症状スケール評価では有意な改善は認めなかった。ただし臨床試験実施により重篤な有害事象を認めなかったことは、今後の治療開発において重要な意義を持つと考えられる。
|
Report
(5 results)
Research Products
(14 results)
-
[Journal Article] Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial.2019
Author(s)
Kotajima-Murakami H, Takano A, Ogai Y, Tsukamoto S, Murakami M, Funada D, Tanibuchi Y, Tachimori H, Maruo K, Sasaki T, Matsumoto T, Ikeda K.
-
Journal Title
Neuropsychopharmacology Reports.
Volume: －
Issue: 2
Pages: 1-10
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
[Journal Article] Increased Serum Levels of Oxytocin in ‘Treatment Resistant Depression in Adolescents (TRDIA)’ Group2016
Author(s)
Tsuyoshi Sasaki, Kenji Hashimoto, Yasunori Oda, Tamaki Ishima, Madoka Yakita, Tsutomu Kurata, Masaru Kunou, Jumpei Takahashi, Yu Kamata, Atsushi Kimura, Tomihisa Niitsu, Hideki Komatsu, Tadashi Hasegawa, Akihiro Shiina, Tasuku Hashimoto, Nobuhisa Kanahara, Eiji Shimizu, Masaomi Iyo
-
Journal Title
PLOS ONE
Volume: e0160767
Issue: 8
Pages: e0160767-e0160767
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder.2015
Author(s)
Sasaki T, Hashimoto K, Oda Y, Ishima T, Kurata T, Takahashi J, Kamata Y, Kimura H, Niitsu T, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M
-
Journal Title
Psychiatry Research
Volume: 228(3)
Issue: 3
Pages: 746-751
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
